Life Sciences Leaders Convene Second Annual Boston Biotech Investor Day

Termeer Institute Joins LabCentral, BioLabs and The Engine to Support Life Sciences Innovators

CAMBRIDGE, Mass., Sept. 4, 2025 /PRNewswire/ -- LabCentral, BioLabs, and The Engine, today announced the second annual Boston Biotech Investor Day (BBID), to be held on Thursday, September 18, 2025. For this second year, the Termeer Institute is joining as a co-host.

This invitation-only Seaport event features 48 early-stage companies developing novel therapies and transformative human health technologies, more than 90 leading investors and pharma partners, and a keynote from Paula Soteropoulos, Chairman of the Board of Ensoma, an in vivo hematopoeitic stem cell (HSC) engineering company.

"Participating entrepreneurs are creating the next generation of therapies to support human health and collectively provide a window into the forefront of the industry," said Maggie O'Toole, CEO of LabCentral. "By bringing them together with the broader ecosystem supporting their work, we are ensuring that these teams have access to the relationships that will help them refine their science and grow their businesses."

"With our focus on empowering a diverse community of life science innovators and supporting the ecosystem around them, we're delighted to join the Boston Biotech Investor Day," said Catharine Smith, Executive Director of the Termeer Institute. "This remarkable community is a vibrant showcase of work that matters deeply to our mission."

"We are delighted to co-host this dynamic event where entrepreneurs solving some of humanity's biggest challenges have the opportunity to forge strong connections across the industry," said Johannes Fruehauf, MD, PhD, Founder and President of BioLabs, and cofounder of Mission BioCapital and LabCentral. "Massachusetts continues to be a global leader in life sciences innovation, and the deep engagement from all parts of the ecosystem at BBID illustrates the widespread commitment to supporting life sciences entrepreneurs."

"Boston Biotech Investor Day exemplifies the power of community to accelerate progress. At a time when the need for transformative health solutions is urgent, this gathering enables critical connections between funders and founders—ensuring new technologies have a pathway to impact," said Emily Knight, President of The Engine.

The day will include a keynote presentation, a panel discussion, 24 entrepreneur pitches and 24 poster presentations with a focus on the issues affecting entrepreneurs and an exploration of the vital work of the participating companies, as well as post-event networking.

Journalists and investors interested in attending should contact [email protected]. 

About LabCentral  
A private, non-profit institution, LabCentral is a launchpad for high-potential life-sciences and biotech start-ups with 243,000 square feet of space across Kendall Square in Cambridge, Mass., and the Harvard University campus. Founded in 2013, LabCentral offers a full complement of programming and networking to life sciences entrepreneurs in addition to fully permitted laboratory and office space for early-stage and growing life sciences companies. In its first eleven years, LabCentral residents raised more than $20 billion in funding and created more than 7,000 jobs.  More information is available at www.labcentral.org.

About the Termeer Institute
The Termeer Institute empowers a diverse, global community of life science innovators and visionaries to transform the human element of healthcare and accelerate cures for patients worldwide.

About BioLabs
BioLabs are the premier coworking spaces for life science startups — unique places where you can test, develop and grow your game-changing ideas. As entrepreneurs and investors ourselves, we have first-hand experience with the pain-points biotech startups face. Our goal is to change how scientific entrepreneurs do business by building an ecosystem that empowers bioinnovators to grow quickly, while maximizing capital efficiency.

About The Engine
The Engine is a nonprofit incubator and accelerator dedicated to supporting early-stage Tough Tech companies tackling the world's greatest challenges. Founded by MIT in 2016, The Engine provides critical support for Tough Tech companies in the form of specialized lab and fabrication infrastructure, programming and mentorship, and an ecosystem of experts and investors. By bridging the gap between groundbreaking ideas and real-world impact, The Engine plays a crucial role in advancing solutions to complex global issues. For more information, visit engine.xyz. Contact: [email protected]

SOURCE LabCentral